J. Safrit

发表

Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques

L. Weinberger, A. Perelson, J. Mittler, 1999, The Journal of experimental medicine.

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

D. Ho, Y. Cao, J. Safrit, 1994, Journal of virology.

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

D. Ho, Y. Cao, L. Zhang, 1995, The New England journal of medicine.

Status of vaccine research and development of vaccines for HIV-1.

J. Safrit, W. Koff, P. Fast, 2016, Vaccine.

An epitope-selective, transporter associated with antigen presentation (TAP)-1/2-independent pathway and a more general TAP-1/2-dependent antigen-processing pathway allow recognition of the HIV-1 envelope glycoprotein by CD8+ CTL.

R. Siliciano, B. Walker, S. Kalams, 1995, Journal of Immunology.

Epidemiology of HIV Infection and Risk in Adolescents and Youth

J. Safrit, P. Wright, Craig M. Wilson, 2010, Journal of acquired immune deficiency syndromes.

Visualization and quantification of T cell–mediated cytotoxicity using cell-permeable fluorogenic caspase substrates

J. Safrit, J. Altman, M. Feinberg, 2002, Nature Medicine.

Sensitivity of human renal cell carcinoma lines to TNF, adriamycin, and combination: role of TNF mRNA induction in overcoming resistance.

A. Belldegrun, J. Safrit, B. Bonavida, 1993, The Journal of urology.

Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance.

J. Safrit, B. Bonavida, 1992, Cancer research.

Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.

J. Mascola, J. Safrit, L. Mofenson, 2020, The Journal of infectious diseases.

Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs

R. Apps, J. Safrit, R. Lynch, 2018, Journal of Virology.

Replication in a Natural Host Species Role for Immune Control of Virus Immunodeficiency Virus Reveals Limited Monkeys Naturally Infected with Simian Cells in Sooty Mangabey + Depletion of CD8

J. Safrit, S. Staprans, M. Feinberg, 2007 .

Hierarchy of in vitro sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs and toxins

J. Safrit, B. Bonavida, 2005, Cancer Immunology, Immunotherapy.

Quantitative assessment of human immunodeficiency virus type 1 replication in human xenografts of acutely infected Hu-PBL-SCID mice.

J. Safrit, R. Koup, M. Somasundaran, 1994, AIDS research and human retroviruses.

HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission

P. Kaleebu, J. Safrit, L. Mofenson, 2014, PLoS medicine.

Transient T cell expansion, activation, and proliferation in therapeutically vaccinated SIV+ macaques treated with N-803

J. Safrit, T. Friedrich, P. Edlefsen, 2022, bioRxiv.

Reversal of Drug Resistance: Synergistic Anti-Tumor Cytotoxic Activity by Combination Treatment with Drug and TNF or Toxins

J. Safrit, B. Bonavida, H. Morimoto, 1993 .

Gender, age, and ethnicity in HIV vaccine-related research and clinical trials: Report from a WHO–UNAIDS consultation, 26–28 August 2004. Lausanne, Switzerland

J. Fuchs, C. Obermeyer, J. Safrit, 2005, AIDS.

A region of the third variable loop of HIV-1 gp120 is recognized by HLA-B7-restricted CTLs from two acute seroconversion patients.

J. Safrit, R. Koup, C. Andrews, 1994, Journal of immunology.

IL-15 Superagonist N-803 Enhances IFN-γ Production of MAIT Cells in SIV+ Macaques

J. Safrit, S. O’Connor, Nadean M. Kannal, 2022, Infection and immunity.

Control of Simian Immunodeficiency Virus Infection in Prophylactically Vaccinated, Antiretroviral Treatment-Naive Macaques Is Required for the Most Efficacious CD8 T Cell Response during Treatment with the Interleukin-15 Superagonist N-803

J. Safrit, T. Friedrich, Ryan V. Moriarty, 2022, Journal of virology.

IL-15 superagonist N-803 enhances IFNγ production and alters the trafficking of MAIT cells in SIV+ macaques

J. Safrit, S. O’Connor, Nadean M. Kannal, 2022, bioRxiv.

IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells

J. Safrit, P. Friedl, J. Jansen, 2020, Cancer Immunology, Immunotherapy.

Control of SIV infection in prophylactically vaccinated, ART-naïve macaques is required for the most efficacious CD8 T cell response during treatment with the IL-15 superagonist N-803

J. Safrit, T. Friedrich, Ryan V. Moriarty, 2022, bioRxiv.

Overcoming drug resistance of ovarian carcinoma cell lines by treatment with combination of TNF- α /anti-Fas antibody and chemotherapeutic drugs or toxins

J. Safrit, J. Berek, S. Yonehara, 1995 .

Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitory drugs in women given intrapartum nevirapine for perinatal HIV prevention: An open-label randomized trial

B. Chi, J. Stringer, J. Safrit, 2008 .

Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics.

Julia E. Aledort, R. Peeling, K. Holmes, 2006, Nature.

Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines.

J. Safrit, B. Bonavida, H. Morimoto, 1991, Journal of immunology.

HIV vaccines in infants and children: past trials, present plans and future perspectives.

J. Safrit, 2003, Current molecular medicine.

Adaptive Evolution of Human Immunodeficiency Virus-Type 1 During the Natural Course of Infection

Steven M. Wolinsky, Michael Daniels, Manohar R. Furtado, 1996, Science.

Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies

J. Safrit, Shiho Tanaka, A. Rice, 2022, bioRxiv.

Heterologous Vaccination with SARS-CoV-2 Spike saRNA Prime followed by DNA Dual-Antigen Boost Induces Robust Antibody and T-Cell Immunogenicity against both Wild Type and Delta Spike as well as Nucleocapsid Antigens

J. Safrit, Shiho Tanaka, A. Rice, 2021 .

Induction of Humoral Immune Responses following Vaccination with Envelope-Containing, Formaldehyde-Treated, Thermally Inactivated Human Immunodeficiency Virus Type 1

T. Wrin, C. Petropoulos, J. Safrit, 2005, Journal of Virology.

An Antigenic Threshold for Maintaining Human Immunodeficiency Virus Type 1-specific Cytotoxic T Lymphocytes

D. Ho, D. Nixon, S. Bonhoeffer, 2000, Molecular medicine.

Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein.

David Montefiori, Guido Silvestri, D. Montefiori, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial

B. Chi, J. Stringer, J. Safrit, 2007, The Lancet.

CD8+ T‐cell‐mediated suppression of HIV replication in the first year of life: association with lower viral load and favorable early survival

J. Safrit, R. Koup, W. Borkowsky, 1997, AIDS.

Induction of Neutralizing Antibodies and Gag-Specific Cellular Immune Responses to an R5 Primary Isolate of Human Immunodeficiency Virus Type 1 in Rhesus Macaques

D. Montefiori, J. Safrit, Hanh Vo, 2001, Journal of Virology.

Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice

J. Safrit, P. Soon-Shiong, M. Cairo, 2021, Journal for ImmunoTherapy of Cancer.

Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803

J. Safrit, T. Friedrich, P. Edlefsen, 2022, Journal of virology.

Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study

J. Safrit, A. Rice, S. Rabizadeh, 2020, bioRxiv.

The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques

J. Safrit, M. Axthelm, Shiho Tanaka, 2020, PLoS pathogens.

Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization.

R. Siliciano, A. Trocha, J. Safrit, 1999, Journal of immunology.

Cytosolic Localization Dependence on TAP1/2 and Mechanisms for for Class I-Restricted Recognition: Processing of HIV-1 Envelope Glycoprotein

R. Siliciano, A. Trocha, J. Safrit, 1999 .

Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope

D. Ho, J. Safrit, R. Koup, 1994, The Journal of experimental medicine.

Errors in Celia Farber's March 2006 article in Harper's Magazine

D. Kuritzkes, J. Safrit, E. Glaser, 2006 .

Immunoprophylaxis to prevent mother-to-child transmission of HIV-1.

N. Haigwood, J. Mascola, J. Safrit, 2004, Journal of acquired immune deficiency syndromes.

Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8+ T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal

C. Kovacs, J. Safrit, A. Danesh, 2020, Journal of Virology.

Conventional early infant diagnosis in Lesotho from specimen collection to results usage to manage patients: Where are the bottlenecks?

J. Safrit, L. Mofenson, L. Guay, 2017, PloS one.

The CD4 Loss in AIDS Patients is not Immunopathologically Mediated

J. Safrit, R. Koup, 1996, Reviews in medical virology.

Susceptibility to Neutralization by Broadly Neutralizing Antibodies Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs

R. Apps, J. Safrit, R. Lynch, 2018, bioRxiv.

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

J. Nabukenya, T. Ndung’u, S. Lewin, 2021, Nature Medicine.

Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells

J. Safrit, J. Lifson, D. Margolis, 2020, Nature.

Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype.

J. Safrit, B. Bonavida, J. Berek, 1993, Gynecologic oncology.

New observations on cellular immune responses to HIV and T-cell epitopes.

J. Safrit, R. Koup, F. Gotch, 1997, AIDS.

Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation and computer-driven algorithm.

D. Nixon, X. Jin, L. Zhang, 2000, AIDS research and human retroviruses.

Combination of CD8β Depletion and Interleukin-15 Superagonist N-803 Induces Virus Reactivation in Simian-Human Immunodeficiency Virus-Infected, Long-Term ART-Treated Rhesus Macaques

J. Safrit, D. Carnathan, G. Silvestri, 2020, Journal of Virology.

The immunology of primary HIV infection: which immune responses control HIV replication?

J. Safrit, R. Koup, 1995, Current opinion in immunology.

Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial

J. Karn, J. Safrit, D. Douek, 2022, Nature Medicine.

The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents

J. Safrit, S. Lawn, L. Bekker, 2006, AIDS.

Depletion of CD8+ Cells in Sooty Mangabey Monkeys Naturally Infected with Simian Immunodeficiency Virus Reveals Limited Role for Immune Control of Virus Replication in a Natural Host Species1

J. Safrit, S. Staprans, M. Feinberg, 2007, The Journal of Immunology.

Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge

J. Safrit, A. Rice, S. Rabizadeh, 2021, Frontiers in Immunology.

A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses

J. Safrit, Shiho Tanaka, A. Rice, 2020, bioRxiv.

Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice

J. Safrit, Shiho Tanaka, A. Rice, 2021, Scientific Reports.

Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma

J. Safrit, P. Soon-Shiong, M. Cairo, 2020, Journal for ImmunoTherapy of Cancer.

Novel approaches in preclinical HIV vaccine research

J. Safrit, W. Koff, 2016, Current opinion in HIV and AIDS.

Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

L. Stamatatos, A. Gettie, J. Blanchard, 2004, Virology.

Reducing stunting among children: the potential contribution of diagnostics

Julia E. Aledort, R. Peeling, K. Holmes, 2006 .

hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120.

J. Safrit, R. Koup, C. Andrews, 1993, AIDS.

Estimating the Global Health Impact of Improved Diagnostic Tools for the Developing World

Julia E. Aledort, F. Girosi, E. Keeler, 2007 .

Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody.

J. Safrit, R. Koup, M. Fung, 1995, The Journal of infectious diseases.

Author Correction: Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells

Cynthia A. Derdeyn, Deanna A. Kulpa, Guido Silvestri, 2020, Nature.

Relationships between Neutralization, Binding, and ADCC of Broadly Neutralizing Antibodies against Reservoir HIV

J. Safrit, R. Lynch, R. B. Jones, 2020, Journal of virology.

HIV-1 Evolution and Disease Progression

S. Bonhoeffer, R. M. May, M. Nowak, 1996, Science.

Hierarchy of Tumor Cell Sensitivity and Resistance to Cytolysis by TNF, Cytotoxic Cells, Bacterial Toxins, and Cytotoxic Drugs

J. Safrit, B. Bonavida, J. Zighelboim, 1990 .

Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+ Memory T Cell Recall Induced by hAd5 S-Fusion + N-ETSD Infection of Autologous Dendritic Cells from Patients Previously Infected with SARS-CoV-2

J. Safrit, A. Rice, S. Rabizadeh, 2020, medRxiv.

The Dual-Antigen Ad5 COVID-19 Vaccine Delivered as an Intranasal Plus Subcutaneous Prime Elicits Th1 Dominant T-Cell and Humoral Responses in CD-1 Mice

J. Safrit, Shiho Tanaka, A. Rice, 2021, bioRxiv.

Dramatic Rise in Plasma Viremia after Cd8 Ϩ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques

L. Weinberger, A. Perelson, Xia Jin, 2022 .

The Landscape of Targeted Immune Responses in the HIV-1 Vaccine Field

Allan C. deCamp, J. Safrit, G. Tomaras, 2016, AIDS research and human retroviruses.

AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques

A. Perelson, J. Safrit, J. Lifson, 2023, Nature Medicine.

Characterization of long-term survivors of human immunodeficiency virus type 1 infection.

D. Ho, L. Zhang, J. Safrit, 1996, Immunology letters.